Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 2Colorectal Neoplasms 2Otorhinolaryngologic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Localized Head and Neck Carcinoma 1Gastrointestinal Neoplasms 1Disease 1Cardiovascular Diseases 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

lutetium Lu 177 dotatate 10Everolimus 5lanreotide 4gallium Ga 68 dotatate 4Nivolumab 4Magnetic Resonance Spectroscopy 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3Temozolomide 3Somatostatin 3Capecitabine 3surufatinib 2pembrolizumab 2copper dotatate CU-64 2cabozantinib 2amino-acid, glucose, and electrolyte solution 2Specimen Handling 2Octreotide 2Lutetium-177 2Lutetium 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2talazoparib 1sintilimab 1repotrectinib 1lenvatinib 1guarana powder 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Tumors × Referral and Consultation × Clear all
NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Barbara Ann Karmanos Cancer Institute

Phase NA Recruiting
120 enrolled
EndocrineGastrointestinalNETPlasma cell

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡